
|Articles|August 1, 2006
- Pharmaceutical Executive-08-01-2006
- Volume 0
- Issue 0
How Far We've Come
In 1981, pharma was a more innocent industry. It stood on the brink of an AIDS epidemic that science had yet to name or understand. Hazards of generics, product lifecycles, and off-label marketing lay years ahead. There were no embryonic stem cells to fight over--nor euphemisms like "overactive bladder syndrome" and "erectile dysfunction" to ease conversations or kick off ad campaigns. Who knew what awaited us? To remember--and to reflect on what shaped modern pharma--we invite you to page through the most significant events of the past quarter century.
Advertisement
Articles in this issue
over 20 years ago
Time Machineover 20 years ago
Getting Betterover 20 years ago
States Curb Marketingover 20 years ago
From the Editor: Take Your Seatover 20 years ago
Viewpoint: In Your Wordsover 20 years ago
Quiz Answersover 20 years ago
Introduction: Pharm Exec at 25Advertisement
Related to this article

DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.

As specialty drug complexity grows, agentic technology puts the right access, adherence, and affordability resources at the provider’s fingertips at prescribing.

J&J’s separations of Kenvue and DePuy Synthes test whether Innovative Medicine and MedTech create more value together than apart.

Dr. Joe Geraci of NetraMark explains how AI analysis of clinical trial data can uncover hidden responder subgroups, separate true drug responders from placebo responders, and potentially rescue drug assets that appeared to fail in Phase II.

Parexel’s Stacy Hurt explains why AI can speed up clinical research but can’t replace the lived experience of patients.

The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania groundbreaking — answered in plain language.

White House withdraws Dr. Heidi Overton’s FDA commissioner nomination amid Senate GOP pushback, Pfizer and Verismo advance in vivo CAR-T manufacturing through new licensing deals, and Infinitus’s Ankit Jain discusses balancing workloads between humans and agentic AI.
Advertisement
Advertisement
Trending on PharmExec
1
Pfizer, Verismo Strike Licensing Deals to Push CAR T Manufacturing In Vivo
2
Keeping Human Expertise at the Center of AI
3
Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout
4
Johnson & Johnson's Strategic Shift: Why Diversification Is Giving Way to Focus
5

